IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v15y2017i1d10.1007_s40258-016-0272-z.html
   My bibliography  Save this article

Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications

Author

Listed:
  • Marina Kostić

    () (University of Kragujevac)

  • Ljiljan Djakovic

    () (Association of patients with Crohn’s disease and Ulcerative colitis)

  • Raša Šujić

    (Association of patients with Crohn’s disease and Ulcerative colitis)

  • Brian Godman

    () (Karolinska Institute, Karolinska University Hospital Huddinge
    University of Strathclyde
    Liverpool University)

  • Slobodan M. Janković

    () (University of Kragujevac)

Abstract

Abstract Background Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. Objective To estimate the costs of treatment including the resources used by patients with IBD in Serbia from a societal perspective. This includes both Crohn’s disease and ulcerative colitis. Methods This cost-of-illness study was conducted to identify direct, indirect and out-of-pocket costs of treating patients with IBD in Serbia. Patients with IBD (n = 112) completed a semi-structured questionnaire with data concerning their utilisation of heath-care resources and illness-related expenditures. All costs were calculated in Republic of Serbia dinars (RSD) at a 1-year level (2014) and subsequently converted to Euros. Median values and ranges were reported to avoid potential distortions associated with mean costs. Results Median total direct costs and total indirect costs per patient per year in patients with Crohn’s disease were 192,614.32RSD (€1602.97) and 28,014.00RSD (€233.13) and 142,267.15RSD (€1183.97) and 21,436.00RSD (€178.39), respectively, in patients with ulcerative colitis. In both groups, the greatest component of direct costs was hospitalisation. Conclusions Costs of IBD in Serbia are lower than in more developed countries for two reasons. These include the fact that expensive biological therapy is currently under-utilised in Serbia and prices of health services are largely controlled by the State at a low level. The under-utilisation of biologicals may change with the advent of biosimilars at increasingly lower prices.

Suggested Citation

  • Marina Kostić & Ljiljan Djakovic & Raša Šujić & Brian Godman & Slobodan M. Janković, 2017. "Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications," Applied Health Economics and Health Policy, Springer, vol. 15(1), pages 85-93, February.
  • Handle: RePEc:spr:aphecp:v:15:y:2017:i:1:d:10.1007_s40258-016-0272-z
    DOI: 10.1007/s40258-016-0272-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-016-0272-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Renee Stark & Hans-Helmut König & Reiner Leidl, 2006. "Costs of Inflammatory Bowel Disease in Germany," PharmacoEconomics, Springer, vol. 24(8), pages 797-814, August.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. repec:spr:pharme:v:35:y:2017:i:12:d:10.1007_s40273-017-0559-4 is not listed on IDEAS

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:15:y:2017:i:1:d:10.1007_s40258-016-0272-z. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Sonal Shukla) or (Rebekah McClure). General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.